Avalyn Pharma Inc. (NASDAQ:AVLN) Receives Average Rating of “Buy” from Analysts

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN) have been given a consensus recommendation of “Buy” by the five analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $59.00.

Several analysts have weighed in on AVLN shares. Jefferies Financial Group started coverage on shares of Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $52.00 target price on the stock. Guggenheim assumed coverage on shares of Avalyn Pharma in a report on Monday, May 25th. They issued a “buy” rating and a $80.00 price target for the company. Evercore began coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They set an “outperform” rating and a $51.00 price objective on the stock. Morgan Stanley began coverage on Avalyn Pharma in a research report on Tuesday, May 26th. They issued an “overweight” rating and a $53.00 target price on the stock. Finally, Wall Street Zen upgraded Avalyn Pharma to a “hold” rating in a research note on Saturday, May 9th.

Avalyn Pharma Trading Down 1.1%

Shares of AVLN stock opened at $28.72 on Friday. The stock’s fifty day simple moving average is $28.80. Avalyn Pharma has a 1-year low of $24.15 and a 1-year high of $33.32. The stock has a market cap of $1.27 billion and a P/E ratio of -1.32.

Avalyn Pharma (NASDAQ:AVLN) last issued its quarterly earnings results on Wednesday, June 3rd. The company reported ($21.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($16.38) by ($5.45).

Insider Transactions at Avalyn Pharma

In other news, Director Jill Carroll acquired 277,778 shares of Avalyn Pharma stock in a transaction dated Friday, May 1st. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $5,000,004.00. Following the completion of the purchase, the director directly owned 2,186,562 shares in the company, valued at $39,358,116. This trade represents a 14.55% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Sr One Capital Management, Llc bought 555,555 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were purchased at an average cost of $18.00 per share, with a total value of $9,999,990.00. Following the acquisition, the insider directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. This trade represents a 34.06% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

About Avalyn Pharma

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.